Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents-Reference-Cited by-同舟云学术

Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents

Published:2016-06-25 Issue:9 Volume:24 Page:4057-4074
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Escalante C. P., ,Chang Y. C.,Liao K.,Rouleau T.,Halm J.,Bossi P.,Bhadriraju S.,Brito-Dellan N.,Sahai S.,Yusuf S. W.,Zalpour A.,Elting L. S.

Funder

Cancer Prevention and Research Institute of Texas

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-016-3310-3.pdf

Reference150 articles.

1. Yusuf SW, Razeghi P, Yeh ET (2008) The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33(4):163–196. doi: 10.1016/j.cpcardiol.2008.01.002

2. Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12(11):620. doi: 10.1038/nrcardio.2015.133

3. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122–3131. doi: 10.1161/01.cir.0000133187.74800.b9

4. Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ (2014) Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer 50(12):2162–2170. doi: 10.1016/j.ejca.2014.05.013

5. National Cancer Institute (2010) Institute NC Targeted cancer therapies. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted . Accessed 09/10/2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications;Drug Design, Development and Therapy;2024-03

2. What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes;OMICS: A Journal of Integrative Biology;2024-03-01

3. Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes;Pharmacological Research;2023-12

4. Women's health, hormonal balance, and personal autonomy;Frontiers in Medicine;2023-06-30

5. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis;Biomedicine & Pharmacotherapy;2022-09